PDS Biotechnology Corporation (PDSB) concluded trading on Wednesday at a closing price of $1.54, with 5.04 million shares of worth about $7.77 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -54.03% during that period and on Wednesday the price saw a gain of about 22.22%. Currently the company’s common shares owned by public are about 36.82M shares, out of which, 36.02M shares are available for trading.
Stock saw a price change of 6.21% in past 5 days and over the past one month there was a price change of 6.21%. Year-to-date (YTD), PDSB shares are showing a performance of -5.52% which decreased to -71.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.20 but also hit the highest price of $6.68 during that period. The average intraday trading volume for PDS Biotechnology Corporation shares is 317.82K. The stock is currently trading 4.34% above its 20-day simple moving average (SMA20), while that difference is down -2.15% for SMA50 and it goes to -43.65% lower than SMA200.
PDS Biotechnology Corporation (NASDAQ: PDSB) currently have 36.82M outstanding shares and institutions hold larger chunk of about 11.35% of that.
The stock has a current market capitalization of $57.62M and its 3Y-monthly beta is at 1.68. It has posted earnings per share of -$1.17 in the same period. It has Quick Ratio of 2.84 while making debt-to-equity ratio of 1.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PDSB, volatility over the week remained 17.81% while standing at 11.34% over the month.
Stock’s fiscal year EPS is expected to rise by 12.41% while it is estimated to decrease by -0.48% in next year. EPS is likely to shrink at an annualized rate of 3.39% for next 5-years, compared to annual growth of 42.97% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on November 01, 2022 offering a Buy rating for the stock and assigned a target price of $10 to it. Coverage by Cantor Fitzgerald stated PDS Biotechnology Corporation (PDSB) stock as an Overweight in their note to investors on June 28, 2021, suggesting a price target of $25 for the stock. On November 10, 2020, H.C. Wainwright Upgrade their recommendations, while on May 27, 2020, Alliance Global Partners Initiated their ratings for the stock with a price target of $4. Stock get an Outperform rating from Noble Capital Markets on March 09, 2020.
